How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-12...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferretti, Francesca, Cannatelli, Rosanna, Benucci, Maurizio, Carmagnola, Stefania, Clementi, Emilio, Danelli, Piergiorgio, Dilillo, Dario, Fiorina, Paolo, Galli, Massimo, Gallieni, Maurizio, Genovese, Giovanni, Giorgi, Valeria, Invernizzi, Alessandro, Maconi, Giovanni, Maier, Jeanette A., Marzano, Angelo V., Morpurgo, Paola S., Nebuloni, Manuela, Radovanovic, Dejan, Riva, Agostino, Rizzardini, Giuliano, Sabiu, Gianmarco, Santus, Pierachille, Staurenghi, Giovanni, Zuccotti, Gianvincenzo, Sarzi-Puttini, Pier Carlo, Ardizzone, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082137/
https://www.ncbi.nlm.nih.gov/pubmed/33936084
http://dx.doi.org/10.3389/fimmu.2021.656362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082137/
https://www.ncbi.nlm.nih.gov/pubmed/33936084
http://dx.doi.org/10.3389/fimmu.2021.656362

Ejemplares similares